Liver Injury in COVID-19: Known and Unknown

Overview

Journal World J Clin Cases

Publisher Baishideng Publishing Group

Specialty General Medicine

Date 2021 Jul 26

PMID 34307548

Citations 8

Authors

Feng Zhou

Jian Xia

Hai-Xia Yuan

Ying Sun

Ying Zhang

Affiliations

Soon will be listed here.

Abstract

Since the first report of the coronavirus disease 2019 (COVID-19) in December 2019 in Wuhan, China, the outbreak of the disease is currently continuously evolving. Previous studies have shown varying degrees of liver damage in patients with COVID-19. However, the exact causes of liver injury and the relationship between COVID-19 and liver injury is unclear. This article describes liver injury induced by COVID-19, analyzes its causes, and discusses the treatment and prognosis of liver damage in patients with COVID-19.

Citing Articles

Insight into COVID-19 associated liver injury: Mechanisms, evaluation, and clinical implications.

Nasir N, Khanum I, Habib K, Wagley A, Arshad A, Majeed A Hepatol Forum. 2024; 5(3):139-149.

PMID: 39006140 PMC: 11237249. DOI: 10.14744/hf.2023.2023.0025.

The Role of APRI, FIB-4, and SAD-60 Scores as Predictors of Mortality in COVID-19 Patients.

Copur B, Surme S, Tuncer G, Bayramlar O Infect Dis Clin Microbiol. 2024; 5(2):144-152.

PMID: 38633008 PMC: 10985813. DOI: 10.36519/idcm.2023.233.

Georgescu D, Lighezan D, Rosca C, Nistor D, Ancusa O, Suceava I Life (Basel). 2024; 14(1).

PMID: 38255641 PMC: 10817629. DOI: 10.3390/life14010025.

Investigating Acute Hepatitis after SARS-CoV-2 Vaccination or Infection: A Genetic Case Series.

Bernasconi E, Biagi M, Di Agostino S, Cursaro C, Felicani C, Ronconi E Biomedicines. 2023; 11(10).

PMID: 37893221 PMC: 10604753. DOI: 10.3390/biomedicines11102848.

Evaluation of Curcumin-Piperine Supplementation in COVID-19 Patients Admitted to the Intensive Care: A Double-Blind, Randomized Controlled Trial.

Askari G, Bagherniya M, Kiani Z, Alikiaii B, Mirjalili M, Shojaei M Adv Exp Med Biol. 2023; 1412:413-426.

PMID: 37378780 DOI: 10.1007/978-3-031-28012-2_22.

References

Arentz M, Yim E, Klaff L, Lokhandwala S, Riedo F, Chong M . Characteristics and Outcomes of 21 Critically Ill Patients With COVID-19 in Washington State. JAMA. 2020; 323(16):1612-1614. PMC: 7082763. DOI: 10.1001/jama.2020.4326. View

Jiang S, Wang R, Li L, Hong D, Ru R, Rao Y . Liver Injury in Critically Ill and Non-critically Ill COVID-19 Patients: A Multicenter, Retrospective, Observational Study. Front Med (Lausanne). 2020; 7:347. PMC: 7324794. DOI: 10.3389/fmed.2020.00347. View

Lei F, Liu Y, Zhou F, Qin J, Zhang P, Zhu L . Longitudinal Association Between Markers of Liver Injury and Mortality in COVID-19 in China. Hepatology. 2020; 72(2):389-398. PMC: 7267515. DOI: 10.1002/hep.31301. View

Mishra K, Naffouj S, Gorgis S, Ibrahim H, Gill S, Fadel R . Liver Injury as a Surrogate for Inflammation and Predictor of Outcomes in COVID-19. Hepatol Commun. 2021; 5(1):24-32. PMC: 7789831. DOI: 10.1002/hep4.1586. View

Bashash D, Olfatifar M, Hadaegh F, Aghdaei H, Zali M . COVID-19 prognosis: what we know of the significance and prognostic value of liver-related laboratory parameters in SARS-CoV-2 infection. Gastroenterol Hepatol Bed Bench. 2020; 13(4):313-320. PMC: 7682969. View

Huang L, Zhang X, Zhang X, Wei Z, Zhang L, Xu J . Rapid asymptomatic transmission of COVID-19 during the incubation period demonstrating strong infectivity in a cluster of youngsters aged 16-23 years outside Wuhan and characteristics of young patients with COVID-19: A prospective contact-tracing.... J Infect. 2020; 80(6):e1-e13. PMC: 7194554. DOI: 10.1016/j.jinf.2020.03.006. View

Wang H, Qiu P, Liu J, Wang F, Zhao Q . The liver injury and gastrointestinal symptoms in patients with Coronavirus Disease 19: A systematic review and meta-analysis. Clin Res Hepatol Gastroenterol. 2020; 44(5):653-661. PMC: 7214284. DOI: 10.1016/j.clinre.2020.04.012. View

Wang M, Yan W, Qi W, Wu D, Zhu L, Li W . Clinical characteristics and risk factors of liver injury in COVID-19: a retrospective cohort study from Wuhan, China. Hepatol Int. 2020; 14(5):723-732. PMC: 7539280. DOI: 10.1007/s12072-020-10075-5. View

Lin Y, Yuan J, Long Q, Hu J, Deng H, Zhao Z . Patients with SARS-CoV-2 and HBV co-infection are at risk of greater liver injury. Genes Dis. 2020; 8(4):484-492. PMC: 7672332. DOI: 10.1016/j.gendis.2020.11.005. View

10.

Huang J, Zheng K, George J, Gao H, Wei R, Yan H . Fatal outcome in a liver transplant recipient with COVID-19. Am J Transplant. 2020; 20(7):1907-1910. PMC: 7262021. DOI: 10.1111/ajt.15909. View

11.

Zhang C, Shi L, Wang F . Liver injury in COVID-19: management and challenges. Lancet Gastroenterol Hepatol. 2020; 5(5):428-430. PMC: 7129165. DOI: 10.1016/S2468-1253(20)30057-1. View

12.

Da B, Mitchell R, Lee B, Perumalswami P, Im G, Agarwal R . Kinetic patterns of liver enzyme elevation with COVID-19 in the USA. Eur J Gastroenterol Hepatol. 2020; 32(11):1466-1469. PMC: 7299115. DOI: 10.1097/MEG.0000000000001792. View

13.

Nishiura H, Kobayashi T, Miyama T, Suzuki A, Jung S, Hayashi K . Estimation of the asymptomatic ratio of novel coronavirus infections (COVID-19). Int J Infect Dis. 2020; 94:154-155. PMC: 7270890. DOI: 10.1016/j.ijid.2020.03.020. View

14.

Wu J, Liu J, Zhao X, Liu C, Wang W, Wang D . Clinical Characteristics of Imported Cases of Coronavirus Disease 2019 (COVID-19) in Jiangsu Province: A Multicenter Descriptive Study. Clin Infect Dis. 2020; 71(15):706-712. PMC: 7108195. DOI: 10.1093/cid/ciaa199. View

15.

Targher G, Mantovani A, Byrne C, Wang X, Yan H, Sun Q . Detrimental effects of metabolic dysfunction-associated fatty liver disease and increased neutrophil-to-lymphocyte ratio on severity of COVID-19. Diabetes Metab. 2020; 46(6):505-507. PMC: 7270805. DOI: 10.1016/j.diabet.2020.06.001. View

16.

Yeo C, Kaushal S, Yeo D . Enteric involvement of coronaviruses: is faecal-oral transmission of SARS-CoV-2 possible?. Lancet Gastroenterol Hepatol. 2020; 5(4):335-337. PMC: 7130008. DOI: 10.1016/S2468-1253(20)30048-0. View

17.

Ji D, Qin E, Xu J, Zhang D, Cheng G, Wang Y . Non-alcoholic fatty liver diseases in patients with COVID-19: A retrospective study. J Hepatol. 2020; 73(2):451-453. PMC: 7141624. DOI: 10.1016/j.jhep.2020.03.044. View

18.

Wang Y, Liu S, Liu H, Li W, Lin F, Jiang L . SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19. J Hepatol. 2020; 73(4):807-816. PMC: 7211738. DOI: 10.1016/j.jhep.2020.05.002. View

19.

Lan N, Thu N, Barrail-Tran A, Duc N, Lan N, Laureillard D . Randomised pharmacokinetic trial of rifabutin with lopinavir/ritonavir-antiretroviral therapy in patients with HIV-associated tuberculosis in Vietnam. PLoS One. 2014; 9(1):e84866. PMC: 3898920. DOI: 10.1371/journal.pone.0084866. View

20.

Lagana S, Kudose S, Iuga A, Lee M, Fazlollahi L, Remotti H . Hepatic pathology in patients dying of COVID-19: a series of 40 cases including clinical, histologic, and virologic data. Mod Pathol. 2020; 33(11):2147-2155. PMC: 7424245. DOI: 10.1038/s41379-020-00649-x. View